- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.01. | Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26 | 3 | Cision News | ||
| 07.01. | Notice of extraordinary general meeting in EQL Pharma AB | 1 | Cision News | ||
| 04.12.25 | EQL Pharma AB: EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO) | 251 | GlobeNewswire (Europe) | As previously announced, EQL Pharma has decided to strengthen its abilities in international commercial affairs, as a part of its European expansion. The Company has recruited Anne D. Jensen for this... ► Artikel lesen | |
| 03.12.25 | EQL Pharma AB: EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO) | 105 | GlobeNewswire (Europe) | EQL Pharma strengthens and re-organizes its Finance Function to put more emphasis on business control and capital allocation. Our current CFO, Anna Jönsson, will take on the role as Head of Accounting.... ► Artikel lesen | |
| 17.11.25 | EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm | 13 | Cision News | ||
| 14.11.25 | EQL Pharma AB: Methenamine Hippurate (branded as Cystohipp©) have gained marketing approval in Germany | 425 | GlobeNewswire (Europe) | EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in Germany, where it is to be provided to patients by EQL's license partner Dr Pfleger under the EQL... ► Artikel lesen | |
| 05.11.25 | EQL Pharma AB: Interim Report April - September 2025 | 113 | GlobeNewswire (Europe) | A tough quarter for EQL
Comments from the CEO
The second quarter of 2025/26 was marked by unforeseen delivery disruptions, resulting in sales growth of only 1%. The EBITDA margin, which was naturally... ► Artikel lesen | |
| EQL PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.10.25 | Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2025/26 | 3 | Cision News | ||
| 06.10.25 | EQL Pharma AB: EQL Pharma in process of recruiting new Chief Commercial Officer (CCO) | 139 | GlobeNewswire (Europe) | EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his position.... ► Artikel lesen | |
| 30.09.25 | Change in number of shares and votes in EQL Pharma AB | 1 | Cision News | ||
| 23.09.25 | EQL PHARMA AB: Mellozzan (melatonin) launched in the UK | 1 | Cision News | ||
| 22.09.25 | EQL Pharma AB: Delivery delays mean that the second quarter and thus the full year 2025/26 will be weaker than expected | 251 | GlobeNewswire (Europe) | EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made... ► Artikel lesen | |
| 11.09.25 | EQL PHARMA AB: Mellozzan (melatonin) approved in Turkey | 2 | Cision News | ||
| 05.09.25 | Exercise of warrants in EQL Pharma AB's incentive programs | 1 | Cision News | ||
| 25.08.25 | EQL Pharma AB: EQL Pharma's Chief Commercial Officer (CCO) sells shares to buy apartment for daughter | 187 | GlobeNewswire (Europe) | EQL Pharma's Chief Commercial Officer (CCO) Alexander Brising has recently sold shares for approximately SEK 2.1 million to pay for an apartment for his daughter who is starting university. "Not a decision... ► Artikel lesen | |
| 21.08.25 | EQL Pharma AB: Bulletin from the annual general meeting in EQL Pharma AB on 21 August 2025 | 198 | GlobeNewswire (Europe) | Today, on 21 August 2025, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and allocation of the company's... ► Artikel lesen | |
| 18.08.25 | The Nomination Committee's proposal for the annual general meeting in EQL Pharma AB | 1 | Cision News | ||
| 08.08.25 | EQL Pharma AB Q2 Profit Falls | 2 | RTTNews | ||
| 08.08.25 | EQL Pharma: Starkes Umsatzwachstum im Q1 2025 trotz leicht verfehlter Gewinnerwartung | 2 | Investing.com Deutsch | ||
| 08.08.25 | EQL Pharma AB: Interim Report April - June 2025 | 391 | GlobeNewswire (Europe) | A strong start to the year - Sales and operating profit growing, good progress in business development
April - June 2025
Consolidated sales during the first quarter, April to June amounted to SEK... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 400,50 | +0,11 % | Breaking Down Vertex Pharmaceuticals: 12 Analysts Share Their Views | ||
| UNITED THERAPEUTICS | 394,90 | -1,03 % | United Therapeutics reports positive phase 1 results for bioengineered liver | ||
| CATALYST PHARMACEUTICALS | 20,330 | +0,40 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| INDIVIOR PHARMACEUTICALS | 27,000 | 0,00 % | XFRA 2IVB: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILINDIVIOR PLC DL... ► Artikel lesen | |
| CAMURUS | 64,95 | -0,15 % | AKTIONÄR-Tipp Camurus: "Top-Pick" - mit Eli Lilly in neue Dimensionen | Die Aktie des schwedischen Biotech-Unternehmens Camurus hat sich in den zurückliegenden Monaten sehr volatil entwickelt. Die Analysten von ABG Sundal Collier (ABGSC) trauen dem Papier allerdings neue... ► Artikel lesen | |
| BAYER | 45,190 | -3,31 % | FDA gibt Netzhaut-Zelltherapie von Bayer-Tochter Orphan-Drug-Status | DJ FDA gibt Netzhaut-Zelltherapie von Bayer-Tochter Orphan-Drug-Status
DOW JONES--Die US-Bayer-Tochter Bluerock hat für ihren Zelltherapie-Kandidaten OpCT-001 von der US-Gesundheitsbehörde FDA... ► Artikel lesen | |
| MERCK KGAA | 127,05 | -1,09 % | EQS-AFR: Merck KGaA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Merck KGaA
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Merck KGaA: Vorabbekanntmachung über die Veröffentlichung... ► Artikel lesen | |
| NOVO NORDISK | 50,55 | -0,02 % | BARCLAYS stuft NOVO NORDISK auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Novo Nordisk auf "Equal Weight" mit einem Kursziel von 360 dänischen Kronen belassen. Die jüngsten Daten zur... ► Artikel lesen | |
| SANOFI | 77,24 | +0,25 % | JEFFERIES stuft SANOFI auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Sanofi auf "Buy" mit einem Kursziel von 100 Euro belassen. Sanofi sei trotz des erwarteten branchenüblichen Wachstums bis... ► Artikel lesen | |
| HARROW | 42,610 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| ELI LILLY | 856,30 | -0,08 % | Lilly bets on Seamless, delving further into genetic medicine for hearing loss | ||
| ASTRAZENECA | 156,30 | -2,31 % | BERENBERG stuft ASTRAZENECA auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Astrazeneca von 145 auf 160 Pence angehoben und die Einstufung auf "Buy" belassen. Zur Jahresmitte dürften Studienergebnisse... ► Artikel lesen | |
| GSK | 20,980 | -2,01 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan GSK vor den am 4. Februar erwarteten Quartalszahlen auf "Underweight" mit einem Kursziel von 1700 Pence belassen. Nach seinem jüngst geschriebenen... ► Artikel lesen | |
| PFIZER | 21,650 | -0,02 % | Dividendenbekanntmachungen (23.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALBERTSONS COMPANIES INC US0130911037 0,15 USD 0,1275 EUR BANK OF NEW YORK MELLON CORPORATION US0640581007 0,53 USD 0,4508 EUR COCA-COLA... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,235 | 0,00 % | Block & Leviton LLP: Aquestive Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation | Boston, Massachusetts--(Newsfile Corp. - January 13, 2026) - Block & Leviton is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) for potential securities law violations. Investors who have... ► Artikel lesen |
EQL PHARMA AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 5,740 Euro und damit +1,95 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EQL PHARMA AB finden Sie auf Wallstreet Online.